Markets

Nektar Therapeutics (NKTR) in Focus: Stock Rises 10.77% - Tale of the Tape

Nektar Therapeutics ( NKTR ) was a big mover last session, as the company saw its shares rise nearly 11% on the day. This jump can be attributable to solid volume too with far more shares changing hands than in a normal session. This broke the recent trend of the company, as the stock is now trading above the volatile price range of $10.95 to $12.54 in the past one-month time frame.

In the last 30 days, this company did not witness any estimate revisions and the Zacks Consensus Estimate has remained unchanged. However, Friday's price action is encouraging, so make sure to keep a close watch on this firm in the near future.

Nektar Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Other attractive players in the healthcare industry include Illumina Inc. ( ILMN ) carrying a Zacks Rank #1 (Strong Buy) along with Ariad Pharmaceuticals Inc. ( ARIA ) and Aeolus Pharmaceuticals Inc. ( AOLS ) with a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

NEKTAR THERAP (NKTR): Free Stock Analysis Report

ILLUMINA INC (ILMN): Free Stock Analysis Report

AEOLUS PHARMACT (AOLS): Get Free Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AOLS ILMN NKTR

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More